Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

OneMedNet (ONMD) Research & Development (2022 - 2025)

OneMedNet (ONMD) has disclosed Research & Development for 4 consecutive years, with $323000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Research & Development rose 8.39% to $323000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $1.4 million, a 32.31% decrease, with the full-year FY2024 number at $1.5 million, down 28.96% from a year prior.
  • Research & Development was $323000.0 for Q3 2025 at OneMedNet, down from $382000.0 in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $931851.0 in Q4 2023 to a low of $298000.0 in Q3 2024.
  • A 4-year average of $491457.4 and a median of $394000.0 in 2023 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: tumbled 63.51% in 2024, then grew 8.39% in 2025.
  • OneMedNet's Research & Development stood at $880638.0 in 2022, then increased by 5.82% to $931851.0 in 2023, then crashed by 63.51% to $340000.0 in 2024, then fell by 5.0% to $323000.0 in 2025.
  • Per Business Quant, the three most recent readings for ONMD's Research & Development are $323000.0 (Q3 2025), $382000.0 (Q2 2025), and $348000.0 (Q1 2025).